Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medicinova (MNOV) EBIT (2021 - 2025)

Medicinova (MNOV) has disclosed EBIT for 8 consecutive years, with -$3.8 million as the latest value for Q4 2025.

  • Quarterly EBIT changed N/A to -$3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$13.3 million for FY2025, 4.79% down from the prior year.
  • EBIT for Q4 2025 was -$3.8 million at Medicinova, down from -$3.4 million in the prior quarter.
  • The five-year high for EBIT was -$201529.0 in Q1 2021, with the low at -$4.3 million in Q2 2021.
  • Average EBIT over 5 years is -$3.1 million, with a median of -$3.3 million recorded in 2023.
  • The sharpest move saw EBIT crashed 1592.07% in 2022, then skyrocketed 70.57% in 2023.
  • Over 5 years, EBIT stood at -$2.1 million in 2021, then tumbled by 85.34% to -$3.9 million in 2022, then skyrocketed by 36.11% to -$2.5 million in 2023, then crashed by 32.89% to -$3.3 million in 2024, then dropped by 14.57% to -$3.8 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$3.8 million, -$3.4 million, and -$3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.